GILD · News · 20261102N

HIV Pipeline Expansion

GILEAD SCIENCES, INC. · 2026-11-02 · Importance 17 · Surprise 24

Gilead plans to present clinical data and real-world evidence from more than 50 studies at HIV Glasgow 2026, including late-breaking data and two oral presentations. The research will cover long-acting HIV treatment and prevention regimens, including twice-yearly and once-weekly options. The presentations could highlight alternatives to daily regimens, but the digest does not report study results or commercial demand.

Key facts

• Gilead planned to present results from more than 50 studies at HIV Glasgow 2026, including late-breaking data and two oral presentations. source
• Gilead announced participation in HIV Glasgow 2026, taking place November 8–11, 2026. source
• Gilead planned to present results highlighting the potential of twice-yearly and once-weekly long-acting HIV treatment and prevention regimens. source